Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 3,286 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Progenitor Cells Clear all

Conditions: Graft Versus Host Disease
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Health Promotion, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: Allogeneic Cell Therapy w/ Tumor-derived Lypho; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia Acute Myeloid
Interventions: Azacitidine, Venetoclax, Revumenib; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
Interventions: Orca-T; Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Hackensack, New Jersey + 3 more

Conditions: Lymphoma, Neutropenia
Interventions: epoetin alfa, filgrastim, recombinant flt3 ligand, recombinant interleukin-3, sargramostim, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 17 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: BeEAM; Drug
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
Interventions: Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus, Stem Cell Transplant; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil; Radiation · Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
Interventions: Campath, Chemo and/or TBI Allo SCT; Drug
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 2
States / cities: Orlando, Florida • Durham, North Carolina

Conditions: Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
Interventions: Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

Conditions: Hematopoietic Stem Cell Transplantation, Cancer
Interventions: care.coach Avatar™; Behavioral
Lead sponsor: Victor Wang; Industry
Eligibility: 19 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gingival Recession, Lack of Keratinized Gingiva (Disorder)
Interventions: progenitor potential of Gingival Mesenchymal cells; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Myeloma
Interventions: Sirolimus, Tacrolimus, Lenalidomide; Drug
Lead sponsor: Sherif S. Farag; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hematopoietic Stem Cell Transplant, Hematologic Diseases, Physical Activity, Prehabilitation
Interventions: Exercise, Prehabilitation Education; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis; Procedure · Radiation · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions: MESENDO, placebo; Biological · Other
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Adult Langerhans Cell Histiocytosis, Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Peripheral Blood Stem Cell Transplantation; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions: anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: Up to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myocardial Ischemia, Congestive Heart Failure, Cardiovascular Disease
Interventions: Intramyocardial injection of autologous CD34-positive cells (stem cells); Biological
Lead sponsor: Losordo, Douglas, M.D.; Individual
Eligibility: 21 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Myeloma, Transplant-eligible Patients
Interventions: Ex-vivo expanded effector cells; Biological
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Bone Marrow Transplant Infection
Interventions: Not listed
Lead sponsor: Karius, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions: beta-glucan, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation

Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Supportive Care Intervention for Outpatient Stem Cell Transplant Patients

Progenitor Potential of Mesenchymal Stem Cells in Palatal Tissue Harvested From Molar and Premolar Sites

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Impact of Prehabilitation in Oncology Via Exercise- Bone Marrow Transplant

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Stem Cell Study for Subjects With Congestive Heart Failure

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time)

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation